Trials / Unknown
UnknownNCT05856487
To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients
A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 228 (estimated)
- Sponsor
- NVP Healthcare · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety NVP-2203 in patients
Detailed description
This study is a multicenter, randomized, double-blind, parallel-group, phase 3 clinical trial to evaluate efficacy and safety of NVP-2203 in patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NVP-2203 | Take it once daily for 8 weeks orally. |
| DRUG | NVP-2203-R1 | Take it once daily for 8 weeks orally. |
| DRUG | NVP-2203-R2 | Take it once daily for 8 weeks orally. |
| DRUG | NVP-2203-R3 | Take it once daily for 8 weeks orally. |
| DRUG | NVP-2203 Placebo | Take it once daily for 8 weeks orally. |
| DRUG | NVP-2203-R1 Placebo | Take it once daily for 8 weeks orally. |
| DRUG | NVP-2203-R2 Placebo | Take it once daily for 8 weeks orally. |
| DRUG | NVP-2203-R3 Placebo | Take it once daily for 8 weeks orally. |
Timeline
- Start date
- 2023-06-30
- Primary completion
- 2024-05-31
- Completion
- 2024-10-31
- First posted
- 2023-05-12
- Last updated
- 2024-03-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05856487. Inclusion in this directory is not an endorsement.